SVF
Level C· Early Human ResearchProspective Study

Timing of intra-articular injection of adipose-derived mesenchymal stem cells affects cartilage integrity and IL-18 expression in spontaneous osteoarthritis: A preclinical study.

Chen MF., Hsu YH., Lin YC., Hu CC., Chiu YT., Ueng SW.

Prospective Study on Knee Osteoarthritis, Osteoarthritis, Cartilage Damage, published in Int Immunopharmacol (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Int Immunopharmacol (2026)
Country
Netherlands
Reported sample size
—
PMID
41448007
DOI
10.1016/j.intimp.2025.115964

Abstract (original English)

Osteoarthritis (OA) is a progressive joint disease primarily characterized by cartilage degradation. A phase I/II clinical trial demonstrated the therapeutic efficacy of a human adipose-derived mesenchymal stem cell (ADMSC) product in patients with knee OA. However, it remains unclear whether its efficacy varies with disease stage or whether a single intra-articular dose offers sustained protection. In this study, we used STR/ort mice-a spontaneous OA model-to evaluate the effects of a single ADMSC injection administered during either early or advancing-stage OA. An additional group received early-stage treatment and was analyzed at a later time point to assess durability. Cartilage integrity, chondrocyte phenotypes, serum cytokines, and subchondral bone structure were examined at three defined time points. Early ADMSC injection significantly reduced matrix-nonproducing chondrocytes, lowered Osteoarthritis Research Society International (OARSI) scores, suppressed aggrecan fragment and matrix metallopeptidase 13 (MMP-13) expression, and increased SRY-box transcription factor 9 (SOX9) levels. In situ RNA hybridization showed that ADMSC xenografts transiently adhered to the cartilage surface and remained detectable post-injection. Micro-computed tomography (micro-CT) demonstrated restored trabecular architecture, while cytokine profiling revealed reduced interleukin-18 (IL-18) lev

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples, often without a control group.

How we grade evidence
AnimalsMesenchymal Stem Cell TransplantationInjections, Intra-ArticularHumansMesenchymal Stem CellsMiceInterleukin-18OsteoarthritisCartilage, ArticularChondrocytes
Face & SkinKneeKnee OsteoarthritisOsteoarthritisCartilage Damage
View on PubMedDOI

Related research